The Company proposed the establishment of the Interventional Medtech Institute, an Industrial Research Institute in Suzhou. 

The Company signed an exclusive license and technology transfer agreement with JenaValve Technology for TAVR products for aortic regurgitation.

The Company obtained NMPA's approval for Syphonet® Stent Retriever、Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter .

The Company's TaurusNXT® Transcatheter Aortic Valve Replacement System and HighLife® TSMVR were approved by the NMPA as an innovative medical device.

The Company completed the the First-in-human clinical trial of the HighLife® TSMVR and GeminiOne TEER.